teleo-codex/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims
claim	health	The chronic inflammation pathway from UPF consumption creates a regenerating source of vascular risk that overwhelms medication efficacy even with perfect adherence	experimental	REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)	2026-04-04	Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control	vida	causal	American Heart Association (REGARDS investigators)	value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action

Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control

The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces reliance on energy-dense, cheap ultra-processed options; (2) continuous UPF consumption maintains chronic systemic inflammation; (3) inflammation-driven vascular damage persists and regenerates even as antihypertensive medications (ACE inhibitors, calcium channel blockers) attempt to lower blood pressure; (4) the medication effect is partially overwhelmed by the continuous inflammatory insult; (5) result is treatment failure despite pharmacological availability and even with medication adherence. This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control—it's not primarily a medication adherence problem but a continuous environmental exposure problem. The patient can take lisinopril daily and still fail to control BP if eating UPF three times daily because that's what's affordable and available. The GLP-1 receptor agonist anti-inflammatory pathway (hsCRP reduction) provides complementary evidence: semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction—the same inflammatory mechanism that UPF drives in the opposite direction.